ResearchMoz

Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment

GBI Research
Published Date » 2013-01-22
No. Of Pages » 94
     
  Indian Pharmaceutical Market Outlook Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment  
     
  Summary  
   
 GBI Researchs new report Indian Pharmaceutical Market Outlook Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment provides in-depth analysis of the trends, issues and challenges facing the Indian pharmaceutical market. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. The Indian pharmaceutical industry grew from $0.8 billion in 1980 to $21.73 billion in 2010 and is expected to grow further as Multinational...
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9

2 Indian Pharmaceutical Market Outlook Introduction 10

3 Indian Pharmaceutical Market Outlook Overview 11
3.1 Global Pharmaceutical Industry Landscape 11
3.2 Macro View of the Indian Pharmaceutical Sector 12
3.3 Demographic Analysis 13
3.3.1 Population Size, Growth, and Structure 13
3.3.2 Crude Death Rate 15
3.3.3 Infant Mortality Rate 16
3.3.4 Life Expectancy at Birth 17
3.4 Driver and Barriers 19
3.4.1 Drivers 19
3.4.2 Barriers 21
3.5 SWOT Analysis of Indian Pharmaceutical Industry 22

4 Indian Pharmaceutical Market Outlook Industry Characteristics 23
4.1 Healthcare Policy 23
4.1.1 National Health Policy 2002 23
4.1.2 National Rural Health Mission 23
4.1.3 National Urban Health Mission 24
4.2 Intellectual Property Rights in India 25
4.2.1 Effect of Patent Laws on Pharmaceutical Production in India 26
4.2.2 Key Impact of the New Patent Laws on India 27
4.2.3 Patent Act 2005 First Step towards Improving IP Protection 27
4.2.4 IPR Enforcement Rules 2007 27
4.2.5 Trademarks Bill 2007 27
4.2.6 Drugs and Cosmetics Act (Amendment) 2008 27
4.3 Drug Distribution Structure 28
4.4 National Pharmaceuticals Pricing Policy 29
4.4.1 Objectives of the Present Policy 29
4.4.2 Key Principles of National Pharmaceuticals Pricing Policy, 2011 29
4.4.3 Principles for Drug Price Control and Determination in National Pharmaceutical Pricing Policy 2011 30
4.4.4 Other Aspects of the Policy 30
4.4.5 Impact Analysis of the Policy 31
4.5 Goods and Services Tax 31
4.5.1 An Introduction to Goods and Services Tax 31
4.5.2 Dual Goods and Services Tax in India 31
4.5.3 Impact on the Pharmaceutical Industry 32
4.6 Direct Tax Code 33
4.6.1 Tax Structure 33
4.6.2 Incentives Available to the Pharmaceutical Sector 33
4.6.3 Road Ahead 33
4.7 Healthcare Spending in India 34
4.8 Insurance and Reimbursement 35
4.8.1 Private Health Insurance 35
4.8.2 Health Insurance Companies Landscape 36

5 Indian Pharmaceutical Market Outlook Market Analysis 37
5.1 Market overview 37
5.1.1 Contract Research and Manufacturing Services 37
5.1.2 Biotech 38
5.1.3 Over-the-Counter Drugs 42
5.1.4 Prescription Drugs 42
5.1.5 Herbal Medicines 43
5.2 Market Segmentation 44

6 Indian Pharmaceutical Market Outlook Market Analysis by Therapeutic Categories 46
6.1 Market Share of Leading Therapeutic Segment 46
6.2 Anti-Infectives 47
6.2.1 Market Size 47
6.2.2 Key Brands and Players 48
6.2.3 Recent Developments 48
6.2.4 Outlook 48
6.3 Cardiovascular System 49
6.3.1 Market Size 49
6.3.2 Recent Developments 50
6.3.3 Outlook 50
6.4 Gastrointestinal 51
6.4.1 Market Size 51
6.4.2 Recent Developments 52
6.4.3 Outlook 52
6.5 Diabetes 53
6.5.1 Market Size 53
6.5.2 Recent Developments 54
6.5.3 Outlook 54
6.6 Central Nervous System 55
6.6.1 Market Size 55
6.6.2 Recent Developments 56
6.6.3 Outlook 56
6.7 Respiratory 57
6.7.1 Market Size 57
6.7.2 Recent Developments 58
6.7.3 Outlook 58
6.8 Dermatology 59
6.8.1 Market Size 59
6.8.2 Recent Developments 60
6.8.3 Outlook 60
6.9 Oncology 61
6.9.1 Market Size 61
6.9.2 Recent Developments 62
6.9.3 Outlook 62

7 Indian Pharmaceutical Market Outlook Key Trends 63
7.1 Rapid Consolidation and Rise of Multinational Corporations in the Indian Pharmaceutical Industry 63
7.1.1 M&A Deals 63
7.1.2 Licensing Deals 65
7.1.3 Partnership Deals 66
7.2 Patent Litigations Favoring Generics 67
7.2.1 Indian Patent Office Revokes Patent for Pfizers Cancer Drug Sutent (sunitinib) 67
7.2.2 Indian Appeals Body Dismisses Bayers Plea for Stay on Natco's Generic Nexavar (sorafenib) 67
7.2.3 Delhi High Court Rules in Favor of Cipla in Roche's Tarceva (erlotinib) Patent Lawsuit 67
7.2.4 Indian Supreme Court Asks Novartis to Scale Down Price of Cancer Drug Glivec (imatinib) 67
7.3 Increasing Importance of Rural Marketing in India 68
7.3.1 Case Study - Novartis Arogya Parivar Case Study 68
7.4 Product Localization and India-Specific Pricing 70
7.4.1 Case Study - GlaxoSmithKline, Localized Business Model 70
7.5 Sales Strategies 71
7.5.1 Case Study - Mankind, Sales Excellence 71
7.6 Patented Products Introduced in Niche Segments 72
7.6.1 Case Study - Mercks Successful Strategy for Patented Products 72
7.7 Actions Taken by Indian Government against Counterfeit Drugs 73

8 Indian Pharmaceutical Market Outlook Competitive Landscape 74
8.1 Key Foreign Companies 74
8.1.1 Sanofi 74
8.1.2 Roche 74
8.1.3 AstraZeneca 75
8.1.4 GlaxoSmithKline 75
8.1.5 Abbott Laboratories 75
8.2 Key Domestic Companies 76
8.2.1 Dr. Reddys Laboratories 76
8.2.2 Lupin 78
8.2.3 Cipla Limited 80
8.2.4 Ranbaxy Laboratories Limited 81
8.2.5 Biocon 83

9 Indian Pharmaceutical Market Outlook The Way Forward 85
9.1 Outlook for the Indian Pharmaceutical Industry 85
9.2 Risks 86
9.2.1 Currency Fluctuation and Financial Problems will make it Difficult to Sustain Growth 86
9.2.2 Regulatory Hurdles 86
9.2.3 Financial Disparity 86
9.2.4 Intellectual Property Concerns 86
9.3 Recommendations 87
9.3.1 Improved Links between Industry and Academia 87
9.3.2 Focus on R&D Initiatives and Skilled Manpower 87
9.3.3 Support for Clinical Trials Sector 87
9.3.4 Quality Drugs to be made Affordable and Accessible 87
9.4 Opportunities Ahead 88
9.5 Strategies for Future Success 88
9.5.1 Increasing Importance of Biosimilars 88
9.5.2 Rural Markets 89

10 Indian Pharmaceutical Market Outlook Appendix 90
10.1 Market Definitions 90
10.2 Abbreviations 90
10.3 Bibliography 92
10.4 Research Methodology 93
10.4.1 Coverage 93
10.4.2 Secondary Research 93
10.4.3 Primary Research 93
10.4.4 Expert Panel Validation 94
10.5 Contact Us 94
10.6 Disclaimer 94

List of Tables


Table 1: Pharmaceutical Market, India, Share of Pharmaceutical Products in Total Exports and Imports (%), 2012 12
Table 2: Pharmaceutical Market, India, Population by Age Group (%), 20012026 13
Table 3: Pharmaceutical Market, India, Crude Death Rate (per 1,000 Population), 19812009 15
Table 4: Pharmaceutical Market, India, Infant Mortality Rate by Sex (per 1,000 Live Births), 19801998 16
Table 5: Pharmaceutical Market, India, Infant Mortality Rate by Sex (per 1,000 Live Births), 19992009 16
Table 6: Pharmaceutical Market, India, Ceiling Price Reduction and Impact, 2012 31
Table 7: Pharmaceutical Market, India, Healthcare Expenditure among BRIC Countries, 2012 35
Table 8: Pharmaceutical Market, India, Indian Biosimilar Companies with Marketed Products in India, 2010 40
Table 9: Pharmaceutical Market, India, Retail Market Revenue ($bn), 20072011 44
Table 10: Pharmaceutical Market, India, Hospital Market Revenue ($m), 20072011 45
Table 11: Pharmaceutical Market, India, Anti-Infectives Market Revenue, ($bn), 20052010 47
Table 12: Pharmaceutical Market, India, Anti-Infectives, Major Companies and Brands, 2011 48
Table 13: Pharmaceutical Market, India, Cardiovascular Market Revenue ($m), 20052010 49
Table 14: Pharmaceutical Market, India, Gastrointestinal Market Revenue, ($m), 20052010 51
Table 15: Pharmaceutical Market, India, Diabetes Market Revenue ($m), 20052010 53
Table 16: Pharmaceutical Market, India, Central Nervous System Market Revenue ($m), 20052010 55
Table 17: Pharmaceutical Market, India, Respiratory Market Revenue ($m), 20052010 57
Table 18: Pharmaceutical Market, India, Dermatology Market Revenue ($m), 20052010 59
Table 19: Pharmaceutical Market, India, Oncology Market Revenue ($m), 20052010 61
Table 20: Pharmaceutical Market, India, Dr. Reddys Laboratories, Strategic Consolidations, 20112012 77
Table 21: Pharmaceutical Market, India, Lupin, Strategic Consolidations, 2011 79
Table 22: Pharmaceutical Market, India, Cipla, Strategic Consolidations, 2012 80
Table 23: Pharmaceutical Market, India, Ranbaxy, Strategic Consolidations, 20112012 82
Table 24: Pharmaceutical Market, India, Biocon, Strategic Consolidations, 20112012 84

List of Figures


Figure 1: Pharmaceutical Market, India, ANDA Filings by Indian Companies, 2012 11
Figure 2: Pharmaceutical Market, India, Growth in Pharmaceutical Products Trade, (%), 20062011 12
Figure 3: Pharmaceutical Market, India, Population by Age Group (%), 20012026 13
Figure 4: Pharmaceutical Market, India, Crude Death Rate (per 1,000 Population), 19812009 15
Figure 5: Pharmaceutical Market, India, Infant Mortality Rate by Sex (per 1,000 Live Births), 19802009 16
Figure 6: Pharmaceutical Market, India, Life Expectancy at Birth, 19012025 17
Figure 7: Pharmaceutical Market, India, Healthcare Indicators in BRIC Countries, 2012 18
Figure 8: Pharmaceutical Market, India, Drivers and Barriers, 2012 19
Figure 9: Pharmaceutical Market, India, Doctors and Nurses (per 10,000 population), 2010 20
Figure 10: Pharmaceutical Market, India, SWOT Analysis 22
Figure 11: Pharmaceutical Market, India, NRHM Progress, 2011 24
Figure 12: Pharmaceutical Market, India, Intellectual Property Rights Protection Framework, 2010 25
Figure 13: Pharmaceutical Market, India, Regulatory Landscape, Intellectual Property Rights Protection, 19632005 26
Figure 14: Pharmaceutical Market, India, Drug Distribution System, 2012 28
Figure 15: Pharmaceutical Market, India, Healthcare Expenditure, 2009 34
Figure 16: Pharmaceutical Market, India, Healthcare Expenditure among BRIC Countries, 2012 34
Figure 17: Pharmaceutical Market, India, Health Insurance Companies Landscape, 2012 36
Figure 18: Pharmaceutical Market, India, Services Outsourced in Value Chain (%), 2011 37
Figure 19: Pharmaceutical Market, India, Biotechnology Market Revenue ($m), 20032011 38
Figure 20: Pharmaceutical Market, India, Biotechnology Market Segmentation (%), 2011 39
Figure 21: Pharmaceutical Market, India, Market by Sub-sector (%), 2011 43
Figure 22: Pharmaceutical Market, India, Retail Market Revenue ($bn), 20072011 44
Figure 23: Pharmaceutical Market, India, Hospital Market Revenue ($m), 20072011 45
Figure 24: Pharmaceutical Market, India, Market Share by Therapy Area, 2005 and 2010 46
Figure 25: Pharmaceutical Market, India, Anti-Infectives Market Revenue ($bn), 20052010 47
Figure 26: Pharmaceutical Market, India, Cardiovascular Market Revenue ($m), 20052010 49
Figure 27: Pharmaceutical Market, India, Gastrointestinal Market Revenue ($m), 20052010 51
Figure 28: Pharmaceutical Market, India, Diabetes Market Revenue ($m), 20052010 53
Figure 29: Pharmaceutical Market, India, Central Nervous System Market Revenue ($m), 20052010 55
Figure 30: Pharmaceutical Market, India, Respiratory Market Revenue ($m), 20052010 57
Figure 31: Pharmaceutical Market, India, Dermatology Market Revenue ($m), 20052010 59
Figure 32: Pharmaceutical Market, India, Oncology Market Revenue ($m), 20052010 61
Figure 33: Pharmaceutical Market, India, Number of M&A Deals, 20072012 63
Figure 34: Pharmaceutical Market, India, M&A Deals, Deals by Value (%), 20072012 64
Figure 35: Pharmaceutical Market, India, Number of Licensing Deals, 20072012 65
Figure 36: Pharmaceutical Market, India, Licensing Deals, Deals by Value (%), 20072012 65
Figure 37: Pharmaceutical Market, India, Number of Partnership Deals, 20072012 66
Figure 38: Pharmaceutical Market, India, Partnership Deals, Deals by Value (%), 20072012 66
Figure 39: Pharmaceutical Market, India, Novartis Arogya Parivar Marketing Mix, 2012 68
Figure 40: Pharmaceutical Market, India, Novartis Arogya Parivar, Factsheet, 2012 69
Figure 41: Pharmaceutical Market, India, Mankind Sales Strategies, 2012 71

Upcoming Reports:

Greece: barey market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the barley market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the barley market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main market...
Greece: industrial bakery machinery market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the industrial bakery machinery market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the industrial bakery machinery market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report...
Underwater Security (Systems and Services) Market - Global Industry Analysis, Market size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
Global energy demand is expected to rise by as much as 50 percent over the next 25 years. This combined with depletion of existing fossil fuel reserves will mean extensive exploration and production activities by the offshore oil and gas industry in the years to come. 75 percent of this increased requirement is expected to come from the developing world. Security provides industries the freedom to find, develop and manage assets and to deliver services and supplies without interference. Being secure is a result of having the correct strategy through innovative technology, supported by...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Ford Recalls 65,000 Fusion Models Due to Issues in Ignition Key
Nov 20, 2014  
If anything defines the world of automobiles currently, it would be recalls. It seems that a flood of automobiles has surrounded the global automobiles industry, which once represented a flourishing and highly profitable industry.  The current automobile giants ordering yet another recall is Ford Motors Co. Ford declared on Tuesday that it is recalling nearly 65,000 sedans from...
3D Printed Heart Model for Better Cardiological Treatment
Nov 20, 2014  
According to research carried out by the American Heart Association’s Scientific Sessions 2014, surgeons will be able to treat complex heart disorders in patients, with the help of a three dimensional experimental printed model of the heart. For surgical planning, most cardiac surgeons make use of two dimensional images of the heart taken by MRI, ultrasound, and X-ray. But the problem is...
Los Angeles Auto Show Kicks Off
Nov 20, 2014  
The Los Angeles Auto Show kicked off on Wednesday with a rather upbeat mood. Motoring machines, industry metrics, and hybrid models – the show has lived up to its reputation once more. The Los Angeles Auto Show has begun touring North America from the Los Angeles Convention Center, and the commencement has already had an impact on the market. Gasoline prices dropped under US$3...
Scottish Government to Inject 200 Million Pounds in the Housing Sector
Nov 19, 2014  
The construction and the housing industries of Scotland will get a major financial boost from the Scottish government in terms of additional funding worth 200 million pounds. The main rationale of such a financial boost is to stimulate the housing sector and also safeguarding employment in the construction industry. The housing minister of Scotland has requested the housing leaders to work...
Quarterly Dividend of $0.10 Declared by Tyson Foods, Inc.
Nov 19, 2014  
A quarterly dividend on November 18th was declared by Tyson Foods, reported Analyst Ratings Network.com. The shareholders of the February 27th record will be awarded a dividend of 0.10 per share on March 13th.  This represents a yield of 0.94% and a $0.40 dividend on an annualized basis. However, the ex-dividend date of this particular dividend is February 25th.  Such...